See more : Theralase Technologies Inc. (TLTFF) Income Statement Analysis – Financial Results
Complete financial analysis of Resverlogix Corp. (RVXCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Resverlogix Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Yora International Inc. (YORI) Income Statement Analysis – Financial Results
- Sino Agro Food, Inc. (SIAF) Income Statement Analysis – Financial Results
- Monterey Bio Acquisition Corporation (MTRYW) Income Statement Analysis – Financial Results
- Jedat Inc. (3841.T) Income Statement Analysis – Financial Results
- Safilo Group S.p.A. (SFL.MI) Income Statement Analysis – Financial Results
Resverlogix Corp. (RVXCF)
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
| Metric | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.80K | 138.17K | 0.00 | 289.95K | 243.64K | 175.06K | 17.59K | 0.00 | 5.90K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.80K | 138.17K | 0.00 | 289.95K | 243.64K | 175.06K | 17.59K | 0.00 | 5.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% |
| Research & Development | 5.51M | 4.52M | 15.80M | 32.23M | 37.79M | 29.88M | 15.68M | 4.19M | -9.81M | -28.43M | -19.36M | 14.88M | 15.11M | 11.40M | 14.60M | 9.57M | 3.03M | 1.25M | 263.92K | 194.13K | 0.00 |
| General & Administrative | 6.94M | 11.12M | 6.49M | 6.51M | 4.07M | 4.27M | 4.33M | 4.27M | -4.23M | -6.21M | -5.27M | 7.52M | 6.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 6.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -753.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.94M | 11.12M | 6.49M | 6.51M | 4.07M | 4.27M | 4.33M | 4.27M | -4.23M | -6.21M | -5.27M | 6.76M | 6.74M | 5.11M | 9.76M | 6.09M | 3.35M | 1.68M | 1.04M | 296.08K | 187.16K |
| Other Expenses | 0.00 | -12.70M | 91.60M | 5.98M | -11.30M | -8.50M | -6.40M | 6.20M | -13.65M | 0.00 | 0.00 | 0.00 | 4.19M | -586.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.71M | 15.85M | 22.58M | 38.74M | 41.86M | 34.14M | 20.01M | 8.46M | -14.04M | -34.64M | -24.63M | 21.29M | 26.27M | 16.74M | 24.82M | 16.00M | 6.59M | 3.05M | 1.41M | 512.83K | 187.30K |
| Cost & Expenses | 12.71M | 15.85M | 22.58M | 38.74M | 41.86M | 34.14M | 20.01M | 8.46M | -14.04M | -34.64M | -24.63M | 21.29M | 26.27M | 16.74M | 24.82M | 16.00M | 6.59M | 3.05M | 1.41M | 512.83K | 187.30K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.03M | 6.19M | 5.82M | 3.71M | 1.69M | 71.00K | 78.00K | 2.80K | 138.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 727.00K | 3.19M | 5.63M | 5.45M | 7.03M | 6.19M | 5.82M | 3.71M | 1.69M | 71.00K | 0.00 | 1.20M | 2.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.01M | 1.11M | 356.00K | 358.00K | 377.00K | 284.00K | 284.00K | 212.00K | 89.00K | 247.00K | 420.00K | 281.00K | 239.99K | 220.48K | 457.24K | 348.76K | 214.28K | 114.89K | 106.06K | 22.62K | 136.84 |
| EBITDA | -11.74M | -14.87M | -21.93M | 86.00M | -30.54M | -28.82M | -26.22M | -3.11M | 73.41M | 26.25M | 30.94M | -21.58M | -26.03M | -16.38M | -24.36M | -15.37M | -6.14M | -2.76M | -1.28M | -490.21K | -187.16K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -928,380.11% | -11,854.78% | 0.00% | -5,299.54% | -2,518.92% | -1,574.34% | -7,300.84% | 0.00% | -3,171.21% |
| Operating Income | -12.75M | -15.97M | -22.96M | 85.64M | -30.90M | -34.14M | -20.01M | -8.46M | -14.04M | -34.64M | -24.63M | -21.86M | -26.27M | -16.60M | -24.82M | -15.71M | -6.35M | -2.87M | -1.39M | -512.83K | -187.30K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -936,940.32% | -12,014.36% | 0.00% | -5,419.82% | -2,606.87% | -1,639.97% | -7,903.73% | 0.00% | -3,173.53% |
| Total Other Income/Expenses | 10.79M | -8.06M | 144.20M | -118.40M | -10.96M | -4.95M | 6.49M | -5.13M | -72.93M | 8.63M | -5.89M | 577.00K | 4.19M | -586.28K | 167.16K | -11.75K | -32.27K | 61.35K | -20.49K | 0.00 | 0.00 |
| Income Before Tax | -3.59M | -24.76M | 118.05M | -162.77M | -58.26M | -46.13M | -19.70M | -19.41M | -55.19M | 44.95M | 18.67M | 2.08M | -22.08M | -17.19M | -24.65M | -15.73M | -6.38M | -2.81M | -1.41M | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -787,524.33% | -12,438.68% | 0.00% | -5,423.87% | -2,620.11% | -1,604.93% | -8,020.21% | 0.00% | 0.00% |
| Income Tax Expense | 18.00K | 12.00K | 27.00K | 29.00K | 47.00K | 83.00K | 11.00K | -1.09M | -82.00K | 1.60M | -117.00K | -23.37M | 5.39M | 916.22K | 3.48M | 821.22K | 0.00 | 27.77K | 0.00 | 0.00 | 0.00 |
| Net Income | -3.61M | -24.77M | 118.03M | -162.80M | -58.31M | -46.21M | -19.72M | -18.32M | -55.10M | 43.36M | 18.78M | 2.08M | -27.47M | -18.10M | -28.13M | -16.55M | -6.38M | -2.84M | -1.41M | -512.83K | -187.30K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -979,683.80% | -13,101.81% | 0.00% | -5,707.10% | -2,620.11% | -1,620.79% | -8,020.21% | 0.00% | -3,173.53% |
| EPS | -0.01 | -0.10 | 0.57 | -0.87 | -0.42 | -0.44 | -0.20 | -0.22 | -0.69 | 0.58 | -0.29 | -0.04 | -0.67 | -0.61 | -1.09 | -0.69 | -0.27 | -0.14 | -0.09 | -0.05 | -0.02 |
| EPS Diluted | -0.01 | -0.10 | 0.54 | -0.87 | -0.42 | -0.44 | -0.20 | -0.22 | -0.69 | 0.58 | -0.29 | -0.04 | -0.67 | -0.61 | -1.09 | -0.69 | -0.27 | -0.14 | -0.09 | -0.05 | -0.02 |
| Weighted Avg Shares Out | 254.42M | 239.87M | 208.25M | 188.10M | 137.74M | 105.35M | 100.98M | 85.08M | 79.50M | 74.22M | 64.62M | 51.35M | 41.10M | 29.64M | 25.84M | 24.10M | 23.82M | 20.56M | 16.06M | 10.73M | 9.42M |
| Weighted Avg Shares Out (Dil) | 254.42M | 239.87M | 221.43M | 188.10M | 137.74M | 105.35M | 100.98M | 85.08M | 79.50M | 74.22M | 64.62M | 52.21M | 41.10M | 29.64M | 25.84M | 24.10M | 23.82M | 20.56M | 16.06M | 10.73M | 9.42M |
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
Calgary, Alberta--(Newsfile Corp. - July 31, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual & Special Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected four (4)...
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges
Calgary, Alberta--(Newsfile Corp. - July 16, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced it has entered into definitive transaction documents for the two-year extension of the Company's US$6.0 million secured convertible debenture (the "Debenture") with Shenzhen Hepalink...
Resverlogix Announces Updated Annual and Special Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will be held on Wednesday, July 31, 2024, commencing at approximately 1:00...
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of...
Resverlogix Announces Change to Its Board of Directors
Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective today. "We would like to thank Shawn for his contributions...
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, "The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation,"...
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
Calgary, Alberta--(Newsfile Corp. - October 4, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells" in...
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
Amsterdam, Netherlands and Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") (TSX:RVX) today announced that new guidelines published by the European Society of Cardiology (ESC) reflect unmet need in the reduction of cardiovascular risk in...
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.
Calgary, Alberta--(Newsfile Corp. - May 21, 2021) - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") announces that on May 13, 2021, it acquired 10% secured convertible debentures due May 13, 2022, of Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) (the...
Source: https://incomestatements.info
Category: Stock Reports